HOME
SEARCH
RSS FEED
SUBSCRIBE
Search Results - tumor+infiltrating+lymphocytes
2
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)
Summary: The NCI seeks parties interested in licensing this library of cell lines stably expressing tumor-specific antigens and HLAs. Description of Technology: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes
tumor infiltrating lymphocytes
(TILs) or genetically engineered T cells to attack tumor cells through...
Published: 4/23/2026
|
Updated: 8/2/2023
|
Inventor(s):
Keywords(s):
act
,
adoptive cell therapy
,
Antigen Presenting Cells
,
APC
,
cell lines
,
HLA
,
Human Leukocyte Antigen
,
Immunotherapy
,
KRAS
,
Levin
,
p53
,
Rosenberg
,
T Cell Receptor
,
TCR
,
TIL
,
Tumor Infiltrating Lymphocytes
,
Tumor-Specific Antigen
Category(s):
Collaboration Sought > Licensing
,
TherapeuticArea > Oncology
,
TherapeuticArea > Immunology
,
Application > Research Materials
,
TherapeuticArea > Infectious Disease
Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients
Summary: NCI seeks commercial partners to co-develop and/or license a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL). Description of Technology: Adoptive cell transfer (ACT) uses
tumor infiltrating lymphocytes
(TILs) that recognize antigens expressed by cancer cells...
Published: 4/24/2026
|
Updated: 8/2/2023
|
Inventor(s):
Rami Yoseph
,
Paul Robbins
,
Frank Lowery
,
Sri Krishna
,
Amy Copeland
,
Steven Rosenberg
Keywords(s):
act
,
Adoptive Cell Transfer
,
Immunotherapy
,
Neoantigen
,
Rosenberg
,
T Cell Receptors
,
TCRs
,
TILS
,
Tumor Infiltrating Lymphocytes
Category(s):
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
Application > Therapeutics
,
TherapeuticArea > Oncology
Home
|
Search
|
RSS
|
Subscribe
© 2026. All Rights Reserved. Powered by
Inteum